Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?

被引：1
|
作者：
Okeya, Aoba [1 ]
Shimomura, Akihiko [2 ]
Kitagawa, Dai [1 ]
Shimizu, Chikako [2 ]
机构：
[1] Natl Ctr Global Hlth & Med, Dept Breast Surg Oncol, Tokyo, Japan
[2] Natl Ctr Global Hlth & Med, Dept Breast & Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 28期
关键词：
ESR1; MUTATIONS;
D O I：
10.1200/JCO.24.00992
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Rugo, Hope S.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal L.
    Delaney, Rosemary
    Fu, Olivia
    Lin, Lanjia
    Verret, Wendy
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) : 3365 - +
  • [32] Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
    Mukai, Hirofumi
    Shimizu, Chikako
    Masuda, Norikazu
    Ohtani, Shoichiro
    Ohno, Shinji
    Takahashi, Masato
    Yamamoto, Yutaka
    Nishimura, Reiki
    Sato, Nobuaki
    Ohsumi, Shozo
    Iwata, Hiroji
    Mori, Yuko
    Hashigaki, Satoshi
    Muramatsu, Yasuaki
    Nagasawa, Takashi
    Umeyama, Yoshiko
    Lu, Dongrui R.
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (03) : 274 - 287
  • [33] Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer
    Mouabbi, Jason A.
    Osborne, C. Kent
    Schiff, Rachel
    Rimawi, Mothaffar F.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (02) : 189 - 201
  • [34] Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S9 - S10
  • [35] Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
    Campone, Mario
    Bardia, Aditya
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Doroumian, Severine
    Pelekanou, Vasiliki
    Celanovic, Marina
    Linden, Hannah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S9 - S10
  • [37] Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer
    Kim, HJ
    Cui, XJ
    Hilsenbeck, SG
    Lee, AV
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 1013S - 1018S
  • [38] Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study (vol 42, 35, 2024)
    Jhaveri, Komal L.
    Lim, Elgene
    Jeselsohn, Rinath
    Ma, Cynthia X.
    Hamilton, Erika P.
    Osborne, Cynthia
    Bhave, Manali
    Kaufman, Peter A.
    Beck, J. Thaddeus
    Sanchez, Luis Manso
    Parajuli, Ritesh
    Wang, Hwei-Chung
    Tao, Jessica J.
    Im, Seock-Ah
    Harnden, Kathleen
    Yonemori, Kan
    Dhakal, Ajay
    Neven, Patrick
    Aftimos, Philippe
    Pierga, Jean-Yves
    Lu, Yen-Shen
    Larson, Timothy
    Jerez, Yolanda
    Sideras, Kostandinos
    Sohn, Joohyuk
    Kim, Sung-Bae
    Saura, Cristina
    Bardia, Aditya
    Sammons, Sarah L.
    Bacchion, Francesca
    Li, Yujia
    Yuen, Eunice
    Estrem, Shawn T.
    Rodrik-Outmezguine, Vanessa
    Nguyen, Bastien
    Ismail-Khan, Roohi
    Smyth, Lillian
    Beeram, Muralidhar
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01) : 114 - 114
  • [39] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
    Li, Junjie
    Wang, Zhonghua
    Shao, Zhimin
    CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
  • [40] ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
    Kalinksy, Kevin
    Abramson, Vandana
    Chalasani, Pavani
    Linden, Hannah M.
    Alidzanovic, Jasmina
    Layman, Rachel M.
    Vranjes, Zivko
    Nangia, Julie R.
    Crew, Katherine D.
    Andric, Zoran
    Milovic-Kovacevic, Marijana
    Trifunovic, Jasna
    Suarez, Jose
    Suster, Matt
    Ptaszynski, Mieke
    Mortimer, Joanne
    CANCER RESEARCH, 2022, 82 (04)
12345